drugset

drugset / Trial / NCT00561990

Nimotuzumab in Adults With Pancreatic Cancer

NCT00561990 ↗

Phase 2/3 Completed 188 enrolled Oncoscience AG Gemeinschaftspraxis für Hämatologie und Onkologie, Köln, Germany · collab Hämatologisch-Onkologische Schwerpunktpraxis, Münster, Germany · collab II. Medizinische Klinik u. Poliklinik, Klinikum rechts der Isar, München, Germany · collab Marienhospital Herne · collab Onkologische Gemeinschaftspraxis, Mülheim, Germany · collab Onkologisches Zentrum III, Medizinische Klinik, Mannheim, Germany · collab Praxis für Internistische Onkologie und Hämatologie, Recklinghausen, Germany · collab University of Kiel · collab

Summary

CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER

Timeline

Start: 2007-09
Primary completion: 2013-01
Completion: 2014-01

Publications

Schultheis B, Reuter D, Ebert MP, Siveke J, Kerkhoff A, Berdel WE, Hofheinz R, Behringer DM, Schmidt WE, Goker E, De Dosso S, Kneba M, Yalcin S, Overkamp F, Schlegel F, Dommach M, Rohrberg R, Steinmetz T, Bulitta M, Strumberg D. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann Oncol. 2017 Oct 1;28(10):2429-2435. doi: 10.1093/annonc/mdx343.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Nimotuzumab	Monoclonal antibody	400 mg	Intravenous

Indications